BIOVIE INC

Company Overview

BioVie Inc. is a clinical-stage biopharmaceutical company developing small-molecule and peptide therapies for neurological/neurodegenerative disorders (lead program bezisterim/NE3107 for Alzheimer’s, Parkinson’s and long COVID neurological symptoms) and an advanced liver disease candidate (BIV201 terlipressin formulation). The company is very small (13 employees) and outsourcing-dependent, with operations driven by clinical milestones, regulatory interactions (including an FDA Office of Scientific Investigations referral tied to prior Phase 3 AD site exclusions), grant funding (e.g., Department of Defense support for long COVID), and ongoing fundraising needs. Recent financials show reduced R&D spend after prior trial wind-downs but no product revenues, a cash balance (~$17.5M as of June 30, 2025) that contrasts with ~ $19M of operating cash used for the year, and explicit going-concern disclosure tied to the need for additional financing.

Executive Compensation Practices

As a small, cash-constrained biotechnology company, BioVie’s executive pay is likely equity-heavy and milestone-oriented: the 10-K highlights material stock-based compensation (ASC 718) and a decline in such compensation in the most recent year, consistent with prior option/award grants timed to earlier development stages. Compensation decisions are likely tied to clinical and regulatory milestones (trial starts, positive Phase outcomes, FDA interactions, grant awards, or partnering/licensing deals) and retention needs for a compact senior team; one-off cash bonuses may be limited given liquidity constraints. Given the company’s recent financings, warrant activity and option exercises are probable drivers of executive behavior (to cover taxes or monetize equity), and changes in reported stock-based comp will materially influence GAAP results and investor perception.

Insider Trading Considerations

Insiders at BioVie will often trade around clearly material events for a small-cap biotech: clinical data releases, site-exclusion or FDA OSI developments, trial initiations/completions, DOD grant milestones, and financing or partnership announcements — all of which can move the stock substantially given low float and thin trading. Regulatory and policy considerations (SEC rules, company blackout periods, and recommended 10b5‑1 plans) are especially important because trial outcomes and FDA correspondence are material nonpublic information; prior AD Phase 3 integrity issues make communications timing particularly sensitive. Finally, because the company has limited cash and recently completed equity offerings and warrant exercises, insider transactions may reflect personal liquidity actions (option/warrant exercises or secondary sales) rather than purely informational signals, so size, timing, and whether trades coincide with company disclosures should be closely examined.